Outcomes of 167 healthy sibling donors after peripheral blood
stem cell mobilization with G-CSF 16 mu g/kg/day: efficacy and
safety

J 2015

Outcomes of 167 healthy sibling donors after peripheral blood stem cell mobilization with G-CSF 16 mu g/kg/day: efficacy and safety

KREJČÍ, Marta, Andrea JANÍKOVÁ, František FOLBER, Zdeněk KRÁL, Jiří MAYER et. al.

Základní údaje

Originální název

Outcomes of 167 healthy sibling donors after peripheral blood stem cell mobilization with G-CSF 16 mu g/kg/day: efficacy and safety

Autoři

KREJČÍ, Marta (203 Česká republika, garant, domácí), Andrea JANÍKOVÁ (203 Česká republika, domácí), František FOLBER (203 Česká republika, domácí), Zdeněk KRÁL (203 Česká republika, domácí) a Jiří MAYER (203 Česká republika, domácí)

Vydání

Neoplasma, Bratislava, Slovenská akademie vied, 2015, 0028-2685

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Slovensko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.961

Kód RIV

RIV/00216224:14110/15:00084608

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.4149/neo_2015_094

UT WoS

000362389600013

Klíčová slova anglicky

sibling donor; PBSC mobilization; G-CSF

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 11. 2015 10:01, Soňa Böhmová

Anotace

V originále

Mobilization of peripheral blood stem cells (PBSC) using the granulocyte colony-stimulating factor (G-CSF) has enabled the collection even from older donors and those with comorbidities. Several clinical parameters have been reported to predict the success of PBSC mobilization. The aim of our study was to evaluate the safety of PBSC donation in a cohort of 167 sibling donors after mobilization with G-CSF 16 mu g/kg/day for 5 days during short- and long term follow-up and to analyse the efficacy, toxicity and factors influencing CD34+ mobilization capacity. All 167 sibling donors completed the established mobilization protocol. The median yield was 7.9x10(6)CD34 cells/kg per recipient weight. The optimal target dose of CD34 cells >= 4.0x10(6)/kg was achieved in 140 donors (84%). Only in 4 donors (2%) was the CD34+ yield < 2x10(6)/kg. No major toxicities occured. Factors associated with higher PBSC yields included age < 55 years (p=0.001), male gender (p=0.004), preapheresis CD34 cell counts > 51/mu L (p < 0.001) and preapheresis leukocyte counts >45.5 x 10(9)/L (p =0.003). Comorbidity score, performance status and donor weight did not significantly influence PBSC yields. Long-term follow-up was possible in 60% (101/167) of the donors. The median length of follow-up from PBSC donation was 11.9 years. Most of these donors reported good or very good general health (91%), and no hematological malignancies were observed. The mobilization of PBSC in sibling donors with G-CSF 16 mu g/kg/day is an effective and safe procedure with no significant short- and long-term toxicities.

Citovat

KREJČÍ, Marta, Andrea JANÍKOVÁ, František FOLBER, Zdeněk KRÁL a Jiří MAYER. Outcomes of 167 healthy sibling donors after peripheral blood stem cell mobilization with G-CSF 16 mu g/kg/day: efficacy and safety. Neoplasma. Bratislava: Slovenská akademie vied, 2015, roč. 62, č. 5, s. 787-792. ISSN 0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo_2015_094.

@article{1316771,
   author = {Krejčí, Marta and Janíková, Andrea and Folber, František and Král, Zdeněk and Mayer, Jiří},
   article_location = {Bratislava},
   article_number = {5},
   doi = {http://dx.doi.org/10.4149/neo_2015_094},
   keywords = {sibling donor; PBSC mobilization; G-CSF},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {Outcomes of 167 healthy sibling donors after peripheral blood stem cell mobilization with G-CSF 16 mu g/kg/day: efficacy and safety},
   volume = {62},
   year = {2015}
}

TY  - JOUR
ID  - 1316771
AU  - Krejčí, Marta - Janíková, Andrea - Folber, František - Král, Zdeněk - Mayer, Jiří
PY  - 2015
TI  - Outcomes of 167 healthy sibling donors after peripheral blood stem cell mobilization with G-CSF 16 mu g/kg/day: efficacy and safety
JF  - Neoplasma
VL  - 62
IS  - 5
SP  - 787-792
EP  - 787-792
PB  - Slovenská akademie vied
SN  - 00282685
KW  - sibling donor
KW  - PBSC mobilization
KW  - G-CSF
N2  - Mobilization of peripheral blood stem cells (PBSC) using the granulocyte colony-stimulating factor (G-CSF) has enabled the collection even from older donors and those with comorbidities. Several clinical parameters have been reported to predict the success of PBSC mobilization. The aim of our study was to evaluate the safety of PBSC donation in a cohort of 167 sibling donors after mobilization with G-CSF 16 mu g/kg/day for 5 days during short- and long term follow-up and to analyse the efficacy, toxicity and factors influencing CD34+ mobilization capacity. All 167 sibling donors completed the established mobilization protocol. The median yield was 7.9x10(6)CD34 cells/kg per recipient weight. The optimal target dose of CD34 cells >= 4.0x10(6)/kg was achieved in 140 donors (84%). Only in 4 donors (2%) was the CD34+ yield < 2x10(6)/kg. No major toxicities occured. Factors associated with higher PBSC yields included age < 55 years (p=0.001), male gender (p=0.004), preapheresis CD34 cell counts > 51/mu L (p < 0.001) and preapheresis leukocyte counts >45.5 x 10(9)/L (p =0.003). Comorbidity score, performance status and donor weight did not significantly influence PBSC yields. Long-term follow-up was possible in 60% (101/167) of the donors. The median length of follow-up from PBSC donation was 11.9 years. Most of these donors reported good or very good general health (91%), and no hematological malignancies were observed. The mobilization of PBSC in sibling donors with G-CSF 16 mu g/kg/day is an effective and safe procedure with no significant short- and long-term toxicities.
ER  -

KREJČÍ, Marta, Andrea JANÍKOVÁ, František FOLBER, Zdeněk KRÁL a Jiří MAYER. Outcomes of 167 healthy sibling donors after peripheral blood stem cell mobilization with G-CSF 16 mu g/kg/day: efficacy and safety. \textit{Neoplasma}. Bratislava: Slovenská akademie vied, 2015, roč.~62, č.~5, s.~787-792. ISSN~0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo\_{}2015\_{}094.

Podrobný výpis o publikaci